BL&H Co., Ltd.

Two FDA advisory committees will meet Nov. 18 to consider whether efficacy and safety data from a small, one-arm, Phase III trial are adequate to support approval of Telesta Therapeutics Inc. 's no

Device Transactions Device financing reached $934 million during 2015's first quarter, a slight increase over Q4's $902 million. ( See Exhibit 1. ) Representing 37% of the financing total, follow-on p

Financings During the first quarter of 2015, start-up companies raised a total of $2.74 billion, the third quarter in a row in which the record has been broken. (Last quarter’s total was $1.46 billion

IN VITRO DIAGNOSTICS Mergers & Acquisitions HalioDx Qiagen NV Qiagen Marseille SA Management of Qiagen NV division Qiagen Marseille SA have formed a new company, HalioDx , through a buy-out